Scoring System for the Development of the National List of Essential Drugs in Thailand.

Slides:



Advertisements
Similar presentations
Medication Management
Advertisements

MEDICINES SELECTION & FORMULARY MANAGEMENT
ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Pharmacologic Treatment of Pediatric Headaches El-Chammas K, Keyes J, Thompson N,
Drug Utilization Review (DUR)
Quality Assurance: Manufacturer & Clinical Aspects  Alan Cohen, M.S. DABR  Paul Naine, MSc. MIPEM  Jim Schewe, PhD, DABMP Accuray Incorporated Elekta.
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
Clinical Pharmacy Basma Y. Kentab MSc..
1 Monitoring medical prescription in the Opole Voivodeship Branch of the NFZ Roman Kolek M.D.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Critical Appraisal of Clinical Practice Guidelines
Background Information : Projected prevalence of arthritis is expected to increase from 2.9 million to 6.5 million Canadians, a rise of 124% (Badley.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat.
Dr. Tahereh Safarnavadeh Clinical Pharmacist The Formulary Process In the Name of GOD.
BACKGROUND Health Care Attitudes and Trends among the Pediatric Prescribing Community Mahesh Narayan 1 MB, MSE, Dimple Patel 1 MS, Peter C. Adamson 1,2,3.
PROPRIETARY NAME EVALUATION AT FDA Jerry Phillips, RPh Associate Director for Medication Error Prevention Office of Drug Safety December 4, 2003.
Clinical Pharmacy Part 2
For Pain or Not for Pain: Methadone Madness
Assessment of Patient Knowledge Regarding Drugs Prescribed and Dispensed in Some Health Insurance Outpatient Clinics in Alexandria.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Using a Comprehensive Occupational Exposure Database to Integrate Members of the Occupational Health Team and Improve Your Occupational Health Program.
Jeffrey S. Barrett, PhD, FCP, Dimple Patel, MS, Bhuvana Jayaraman, BS, Mahesh Narayan, MS, Athena Zuppa, MD, FCP Laboratory for Applied PK/PD, Division.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Should developing countries continue to use older drugs for essential hypertension? A prescription survey in South Africa suggested that prescribers were.
IMPACT OF AN ESSENTIAL DRUGS LIST AND TREATMENT GUIDELINES ON PRESCRIBING IN SOUTH AFRICA In 1998 the National Department of Health (NDOH) published standard.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from.
Origin and Process of Utah Guidelines Anna Fondario, MPH Utah Department of Health Violence and Injury Prevention Program.
Evidence-Based Medicine: What does it really mean? Sports Medicine Rounds November 7, 2007.
Determinants of Rational Use of Medicines Dr A K Sharma Prof & Head Dept of Pharmacology AFMC, Pune.
INNOVATIVE LEARNING METHODS FOR RATIONAL DRUGS PRESCRIBING. ITTHIPANICPONG C.,CHOMPOOTAWEEP S., CHONGTRAKUL P., NANTAWAN P., THAMAREE S., WITTAYALERTPANYA.
COMPARATIVE ANALYSIS OF SELECTED ESSENTIAL DRUG LISTS AZIZ JAFAROV/RICHARD LAING.
Assessment of the Selection Process for the 2004 National List for Essential Drugs (NLED) of Thailand Yoongthong W 1, Kunaratanapruk S 1, Sumpradit N 1,
Introduction.
MEDICATION MANAGEMENT P&T COMMITTEE AND FORMULARY MANAGEMENT EMTENAN ALHARBI, Msc CLINICAL PHARMACIST.
Selection of essential medicines Richard Laing and Deidre Dimancesco TBS 2011 Department of Essential Medicines & Pharmaceutical Policies TBS 2008.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
WHO PRESCRIBING INDICATORS (1991 – 1995) TRENDS AND PERSPECTIVES IN AN OUTPATIENT HEALTH CARE FACILITY IN BENIN CITY, NIGERIA. 1 Isah AO, 2 Isah EC, 3.
The Effects of Managerial Intervention on Drug Prescribing Patterns at King Chulalongkorn Memorial Hospital Limpanathikul W, Wangsaturaka D, Nantawan P,
WHO, Dept. Essential Drugs and Medicines Policy Measuring use of medicines: progress in the last decade Kathleen Holloway and Verica Ivanovska Dept. Essential.
Medicines use in primary care in developing and transitional countries Results from studies reported between Kathleen Holloway, Verica Ivanovska,
Initiatives Drive Pediatric Drug Development January 30, 2002.
Medical Certification on Cause of Death Session V: Verbal Autopsy.
IMPACT OF INTRODUCTION OF STATINS TO THE PRIVATE AND STATE SECTORS IN SRI LANKA ON UTILISATION, COST AND PRESCRIPTION PATTERN Galappatthy P Cooray BPR.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
A SIMPLE METHOD FOR ASSESSING IRRATIONAL PRESCRIBING AND PRIORITIZING PRESCRIBING PROBLEMS FOR INTERVENTION: A PILOT STUDY IN UGANDA Hansen EH, Trap B.
DOES DRUG USE EVALUATION (DUE) REQUIRED BY NATIONAL POLICY IMPROVE USE OF MEDICINES?
Does Drug Use Evaluation Required by National Policy Improve Use of Medicines? Akaleephan C*, Muenpa R**, Sittitanyakit B***, Treesak C #, Cheawchanwattana.
Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.
EVALUATING THE EFFECTIVENESS OF THE AGS UPDATED 2012 BEERS CRITERIA AS AN EDUCATIONAL TOOL IN A FAMILY MEDICINE RESIDENCY TRAINING PROGRAM Eseoghene Abokede.
PRAGMATIC Study Designs: Elderly Cancer Trials
Building an Evidence-Based Nursing Practice
(International Program)
Omitted, Delayed or Early Medication Doses
8. Causality assessment:
Accreditation Canada Medicine Accreditation 2016.
Pharmaceutical Care Plan
Polypharmacy In Adults: Small Test of Change
Things to Remember… PubMed
Adherence, attitude to Standard Treatment Guidelines in clinical practice at tertiary care hospitals in Delhi State 1Sangeeta Sharma, 2Sharma KK, 3Sethi.
Abstract Impact of the National Healthcare Reform on Prescribing Patterns of Promotional Targeted Drugs among Thai Physicians Layton MR*, Chadbunchachai.
Impact of an essential drugs list and treatment guidelines on prescribing in South Africa.
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
Toktobaeva B, Karymbaeva S Drug Information Centre Kyrgyzstan
Ethical Considerations for Pediatric Clinical Investigations
Sabaydee.
Regulatory Perspective of the Use of EHRs in RCTs
Assessment of the Selection Process for the 2004 National List for Essential Drugs (NLED) of Thailand Yoongthong W1, Kunaratanapruk S1, Sumpradit N1,
Presentation transcript:

Scoring System for the Development of the National List of Essential Drugs in Thailand.

Dr. Pisonthi Chongtrakul M. D Dr.Pisonthi Chongtrakul M.D. Thai Board of Pediatrics Department of Pharmacology The Faculty of Medicine Chulalongkorn University Bangkok, Thailand.

Introduction The concept of ‘Essential Drugs’ was first introduced by WHO in 1977 It addresses the problems of access, rational use and drug quality. Essential medicines are those that satisfy the priority health care needs of the population. Exactly which medicines are regarded as essential remains a national responsibility.

Background: Thailand has adopted the ED policy and produced several National List of Essential Drug (NLED) since 1979. A new method of scoring system has been introduced and officially used to assist the expert panels in 2004 NLED selection process. This 2004 NLED is also intended to be the reference list for all health care reimbursement schemes.

Objectives: To describe the scoring scheme (ISafE scoring system) that Thailand has adopted for the drug selection process for the 2004 NLED. To describe the evidence-based process included in the drug selection methodology.

Methods: ISafE score uses 5 criteria to assess drug’s overall quality when the drug is used in a pre-defined indication. These criteria are Information, Safety, patient compliance as represented by (drug) adminis- tration restriction + frequency of administration and Efficacy. A point of 0.5 to 1 is assigned to each of the criteria, final ISafE score is the multiplication of all points. Drugs which ranks were below the 50th percen- tile of the list was designated low priority, and high priority drugs should be considered first.

Example of Microsoft Excel Worksheet for ISaFE Score Calculation for Low-Ceiling Diuretics indicated for Hypertension  EV column shows that there are 221 RCTs, Meta-analyses and Academic reviews on HCTZ for Hypertension (from Pubmed search), with overall Excellent quality (from Micromedex CCIS evaluation).  I column is the point assigned to each of the drug in comparison using data in EV column. (Note 2N = 2 publications, no data in CCIS)  All drugs are effective (E) in MM (Micromedex database) column, except tripamide where the evaluation of effectiveness was not available.

Example of Microsoft Excel Worksheet for ISaFE Score Calculation for Low-Ceiling Diuretics indicated for Hypertension  EV column shows that there are 221 RCTs, Meta-analyses and Academic reviews on HCTZ for Hypertension (from Pubmed search), with overall Excellent quality (from Micromedex CCIS evaluation).  I column is the point assigned to each of the drug in comparison using data in EV column. (Note 2N = 2 publications, no data in CCIS)  All drugs are effective (E) in MM (Micromedex database) column, except tripamide where the evaluation of effectiveness was not available.

IES score is the multiplication of I, E and S points, the score closer to 1 represents excellent evidence, proven efficacy and better safety profile.  Drug Risk profiles are tallied from the quantity of Contraindi- cations, Severe ADR and Drug Interactions derived from 3 databases i.e. Micromedex CCIS + Medscape(M) and Clinical Pharmacology(C).  From the example below, there are 31 and 65 total risks of HCTZ manifested in M and C database respectively. (minimum S point = 0.8)  Drug Risk profiles are tallied from the quantity of Contraindi- cations, Severe ADR and Drug Interactions derived from 3 databases i.e. Micromedex CCIS + Medscape(M) and Clinical Pharmacology(C).  From the above example, there are 31 and 65 total risks of HCTZ manifested in M and C database respectively. (minimum S point = 0.8)

ISafE score is the multiplication of IES and af score ISafE score is the multiplication of IES and af score. Drugs with ISafE score not less than 50 percentile are first considered for inclusion into the NLED list, thus Tripamide is put aside.  Compliance is addressed by a (administration restriction e.g. the drug has to be taken on an empty stomach, a = 0.9) and f (frequency of drug administration, e.g. qd dosage, f = 1.0 is preferrable than tid dosage, f = 0.9). The af score is the product of a and f (possible minimum score = 0.9 x 0.85)

NLED score comes from dividing drug cost by ISafE score NLED score comes from dividing drug cost by ISafE score. The score is used to classify NLED list into Class 1 and Class 2 drugs.  Baht/PD = Cost of drug in Baht per day, using WHO defined daily dose and average cost of generic and original drugs.Thus NLED score for HCTZ = 0.13/0.88 = 1.0  A drug with low NLED score is in principle, a drug with high overall quality and low cost.

Criteria for NLED Class 1a (ก), 1b (ข), 2a (ค) and 2b (ง) comes from 25th, 40th, 55th and 70th percentile of the NLED Score respectively.  Class 1 = Basic essential drugs for all level of health care. Class 1a (ก) = Drug of First Choice / Class 1b (ข) = Alternative Drug.  Class 2 = Drugs which need to be prescribed using specialized diagnostic or monitoring facilities, and/or specialist medical care. Class 2a (ค) can be prescribed only by designated experienced physicians and Class 2b (ง) only by trained specialists.

Results: About 150 NLED score worksheets have been created. The list proposed by the scoring system was very well accepted by the expert panels. The scoring system could enhance the productivity and objectivity of the selection process for all parties involved.

Conclusions: A new method of scoring system, using evidence-based data has been adopted for drug selection in Thailand’s 2004 NLED list. The methodological and systematic approach of the scheme is essential for the transparency of the selection process. The drugs included on the list are assured of possessing high overall quality at a reasonable cost. The ISafE scoring system is a tool that can enhance the rational use of drugs.

Thank You